Phosphodiesterase 5 Inhibitors
"Phosphodiesterase 5 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that specifically inhibit PHOSPHODIESTERASE 5.
| Descriptor ID |
D058986
|
| MeSH Number(s) |
D27.505.519.389.735.500
|
| Concept/Terms |
Phosphodiesterase 5 Inhibitors- Phosphodiesterase 5 Inhibitors
- Inhibitors, Phosphodiesterase 5
- Phosphodiesterase Type 5 Inhibitors
- PDE-5 Inhibitors
- Inhibitors, PDE-5
- PDE 5 Inhibitors
- PDE5 Inhibitors
- Inhibitors, PDE5
|
Below are MeSH descriptors whose meaning is more general than "Phosphodiesterase 5 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Phosphodiesterase 5 Inhibitors".
This graph shows the total number of publications written about "Phosphodiesterase 5 Inhibitors" by people in this website by year, and whether "Phosphodiesterase 5 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 4 | 0 | 4 |
| 2014 | 1 | 1 | 2 |
| 2015 | 5 | 0 | 5 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phosphodiesterase 5 Inhibitors" by people in Profiles.
-
Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts. Cell Rep Med. 2022 06 21; 3(6):100541.
-
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children. Pediatr Pulmonol. 2021 03; 56(3):593-613.
-
Results of the FUEL Trial. Circulation. 2020 02 25; 141(8):641-651.
-
Targeting Phosphodiesterase-5 by Vardenafil Improves Vascular Graft Function. Eur J Vasc Endovasc Surg. 2018 08; 56(2):256-263.
-
Design and rationale of the Fontan Udenafil Exercise Longitudinal (FUEL) trial. Am Heart J. 2018 07; 201:1-8.
-
VISION LOSS IN A PATIENT WITH PRIMARY PULMONARY HYPERTENSION AND LONG-TERM USE OF SILDENAFIL. Retin Cases Brief Rep. 2017 Fall; 11(4):325-328.
-
A Case Report of Fatal Desmethyl Carbodenafil Toxicity. J Anal Toxicol. 2017 Apr 01; 41(3):250-255.
-
Translational Perspective on the Role of Testosterone in Sexual Function and Dysfunction. J Sex Med. 2016 08; 13(8):1183-98.
-
Sildenafil treatment in a nonsevere hypertensive murine model lowers blood pressure without reducing fetal growth. Am J Obstet Gynecol. 2016 09; 215(3):386.e1-8.
-
Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016 Apr; 13(4):465-88.